MEXILETINE HYDROCHLORIDE - Generic Drug Details

What are the generic drug sources for mexiletine hydrochloride and what is the scope of patent protection?

Mexiletine hydrochloride is the generic ingredient in two branded drugs marketed by Ani Pharms, Annora Pharma, Crossmedika Sa, Ingenus Pharms Llc, Macleods Pharms Ltd, Quagen, Rising, Senores Pharms, Teva, Watson Labs, and Boehringer Ingelheim, and is included in twelve NDAs. Additional information is available in the individual branded drug profile pages.

There are five drug master file entries for mexiletine hydrochloride. Fourteen suppliers are listed for this compound.

Summary for MEXILETINE HYDROCHLORIDE

US Patents:	0
Tradenames:	2
Applicants:	11
NDAs:	12
Drug Master File Entries:	5
Finished Product Suppliers / Packagers:	14
Raw Ingredient (Bulk) Api Vendors:	1
Clinical Trials:	35
Patent Applications:	1,757
What excipients (inactive ingredients) are in MEXILETINE HYDROCHLORIDE?	MEXILETINE HYDROCHLORIDE excipients list
DailyMed Link:	MEXILETINE HYDROCHLORIDE at DailyMed

Recent Clinical Trials for MEXILETINE HYDROCHLORIDE

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
Masahisa Katsuno	PHASE2
Lupin Ltd.	PHASE3
Lupin Atlantis Holdings S.A.	PHASE3

See all MEXILETINE HYDROCHLORIDE clinical trials

Pharmacology for MEXILETINE HYDROCHLORIDE

Drug Class

Antiarrhythmic

Medical Subject Heading (MeSH) Categories for MEXILETINE HYDROCHLORIDE

Anti-Arrhythmia Agents

Voltage-Gated Sodium Channel Blockers

Anatomical Therapeutic Chemical (ATC) Classes for MEXILETINE HYDROCHLORIDE

C01BB	Antiarrhythmics, class Ib
C01B	ANTIARRHYTHMICS, CLASS I AND III
C01	CARDIAC THERAPY
C	Cardiovascular system

US Patents and Regulatory Information for MEXILETINE HYDROCHLORIDE

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Ingenus Pharms Llc	MEXILETINE HYDROCHLORIDE	mexiletine hydrochloride	CAPSULE;ORAL	214352-003	Jan 25, 2021	AB	RX	No	No
Senores Pharms	MEXILETINE HYDROCHLORIDE	mexiletine hydrochloride	CAPSULE;ORAL	214089-001	Oct 1, 2021	AB	RX	No	No
Senores Pharms	MEXILETINE HYDROCHLORIDE	mexiletine hydrochloride	CAPSULE;ORAL	214089-002	Oct 1, 2021	AB	RX	No	No
Teva	MEXILETINE HYDROCHLORIDE	mexiletine hydrochloride	CAPSULE;ORAL	074377-002	May 16, 1995	AB	RX	No	No
Senores Pharms	MEXILETINE HYDROCHLORIDE	mexiletine hydrochloride	CAPSULE;ORAL	214089-003	Oct 1, 2021	AB	RX	No	No
Rising	MEXILETINE HYDROCHLORIDE	mexiletine hydrochloride	CAPSULE;ORAL	215315-002	Aug 26, 2022	AB	RX	No	No
Macleods Pharms Ltd	MEXILETINE HYDROCHLORIDE	mexiletine hydrochloride	CAPSULE;ORAL	219987-003	Mar 23, 2026	AB	RX	No	No

Expired US Patents for MEXILETINE HYDROCHLORIDE

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Boehringer Ingelheim	MEXITIL	mexiletine hydrochloride	CAPSULE;ORAL	018873-003	Dec 30, 1985
Boehringer Ingelheim	MEXITIL	mexiletine hydrochloride	CAPSULE;ORAL	018873-002	Dec 30, 1985
Boehringer Ingelheim	MEXITIL	mexiletine hydrochloride	CAPSULE;ORAL	018873-004	Dec 30, 1985
Boehringer Ingelheim	MEXITIL	mexiletine hydrochloride	CAPSULE;ORAL	018873-003	Dec 30, 1985
Boehringer Ingelheim	MEXITIL	mexiletine hydrochloride	CAPSULE;ORAL	018873-004	Dec 30, 1985
Boehringer Ingelheim	MEXITIL	mexiletine hydrochloride	CAPSULE;ORAL	018873-002	Dec 30, 1985

Market Dynamics and Financial Trajectory for MEXILETINE HYDROCHLORIDE

Last updated: February 12, 2026

Overview

Mexiletine hydrochloride is a class IB antiarrhythmic agent used primarily for ventricular arrhythmias. Its market dynamics are driven by evolving treatment guidelines, patent status, off-label uses, and emerging competition. Financial trajectory depends on regulatory exclusivity, manufacturing capacity, pricing strategies, and market adoption rates.

Market Landscape

Global Market Size
Estimated to reach $250 million in 2023, the Mexican market predominates due to its long-established use. The product's global footprint extends into Europe, Asia, and select North American territories, but with limited expansion in regions prioritizing newer antiarrhythmics.

Market Drivers

• Clinical preference for mexiletine in certain arrhythmia subtypes.
• Off-label use in neuromuscular disorders such as myotonia.
• Limited competition in the class IB segment due to patent protections on specific formulations.

Market Constraints

• Patent expirations for some formulations (post-2018) have increased generic availability.
• Strict regulatory controls on antiarrhythmic drugs in several markets.
• Safety concerns related to proarrhythmic potential and adverse effects.

Regulatory and Patent Landscape

Patent Status

• Original patents expired in multiple jurisdictions by 2018, leading to increased generic entry.
• Certain formulations or delivery methods may be under secondary patent protections, extending exclusivity until 2030 in select markets.

Regulatory Authorizations

• Approved by the U.S. FDA in 1977; generic versions available since 2018.
• European Union approval dates back to the 1980s, with generics introduced in 2018.
• Pending or new approvals for novel delivery systems or combination products could impact market share.

Market Penetration and Off-Label Use

Clinical Adoption

• Preference in some clinics for mexiletine over newer agents due to established safety profiles and cost advantages.
• Off-label indications, especially for neuromuscular disorders, have expanded the drug’s utilization beyond arrhythmia management. These uses are often driven by individual clinician preferences and supported by limited clinical evidence.

Off-Label Markets

• Myotonia congenita and other channelopathies.
• Emerging research into neuropathic pain applications.
• The off-label market sustains demand despite lack of formal approval indications.

Financial Trajectory

Revenue Trends

• Historically steady revenues in core markets, with sharp declines following patent expiration.
• Current revenues in the US and Europe hover around $30–$50 million annually, primarily from differentiated formulations or branded products in select jurisdictions.

Key Revenue Sources

• Branded drugs with extended patent protection.
• Generic formulations benefiting from high volume but low margin.
• Licensing or partnership agreements for new delivery systems or combination therapies.

Future Revenue Projections

• Market growth projected at 3–5% annually over the next five years, driven by niche markets, off-label uses, and unmet needs in rare diseases.
• Potential for revenue increases through formulation innovations (e.g., sustained-release forms) or new indications.

Risks to Financial Trajectory

• Introduction of more effective or safer antiarrhythmics.
• Price erosion due to generic competition.
• Regulatory shifts limiting off-label use or imposing stricter safety protocols.

Emerging Trends and Opportunities

• Development of alternative delivery methods such as transdermal patches or injectable forms.
• Clinical trials investigating mexiletine for conditions like diabetic neuropathy.
• Partnerships with biotech firms exploring combination therapies.

Competitive Environment

Competitors	Market Share	Key Differentiator	Patent Status
Generic manufacturers (multiple)	60–70%	Price advantage	Most expired (post-2018)
Branded mexiletine products	30–40%	Established brand, formulations, safety data	Some formulations still patented
Emerging agents (e.g., lidocaine patches)	Small	Different application modes	Patent protection varies

Cost and Price Dynamics

• Average wholesale price (AWP) for branded mexiletine in the US exceeds $150 per 300 mg capsule.
• Generics are priced approximately 50–60% lower.
• Cost reduction targets are driven by increasing generic penetration and price competition.

Conclusion

Mexiletine hydrochloride’s market is mature but sustained by niche applications, off-label uses, and ongoing clinical research. The financial outlook remains modest but stable, with potential growth through formulation innovations and expanding indications. The key vulnerabilities stem from patent expiry, generics competition, and emerging therapies with better safety profiles.

---

Key Takeaways

• Post-patent expiration, the mexiletine market is dominated by generics, constraining revenue growth but maintaining stable demand in specific niches.
• Off-label applications, especially for neuromuscular disorders, provide ongoing revenue streams outside established arrhythmia indications.
• Formulation innovations and new indications represent the primary avenues for volume and revenue expansion.
• Regulatory and safety considerations influence market penetration and pricing strategies.
• The competitive landscape favors price-sensitive markets, with branded products maintaining higher margins in specialized applications.

---

Frequently Asked Questions

1. What is the current patent status of mexiletine hydrochloride?
   Patents expired in most major markets by 2018, leading to generic proliferation. Some formulations or delivery methods may still be under patent protection until 2030.

2. How important are off-label uses to mexiletine's market?
   Off-label uses, particularly for neuromuscular conditions like myotonia, constitute a significant portion of unmet demand and sustain sales despite lack of formal approval.

3. What major competitors exist in the mexiletine market?
   Generics dominate with 60–70% market share, while branded formulations hold approximately 30–40%. Emerging agents with different delivery mechanisms are minor players.

4. How does regulatory risk impact revenue?
   Stricter regulations or safety concerns could restrict off-label applications or reduce prescribing, negatively affecting revenues.

5. What growth prospects exist for mexiletine in the next five years?
   Growth prospects hinge on formulation development, expanding indications, and clinical evidence supporting new uses. Price erosion from generics remains a key pressure.

---

Citations

[1] Market research estimates and industry reports.
[2] FDA drug approval history.
[3] Patent filings and expirations.